Core Insights - The OASIS 4 phase 3 trial demonstrated that oral semaglutide 25 mg (Wegovy® in a pill) achieved an average weight loss of 16.6% over 64 weeks, significantly outperforming the placebo group, which saw only 2.7% weight loss [1][3] - The trial included 307 adults with obesity or overweight and showed that 34.4% of participants on oral semaglutide lost 20% or more of their body weight, compared to 2.9% for placebo [1][3] - Oral semaglutide also improved cardiovascular risk factors and daily activity levels, aligning with previous results from injectable Wegovy® [1][3] Company Insights - Novo Nordisk is preparing for the potential FDA approval of oral semaglutide, with production already underway in the US to meet anticipated demand [2][3] - The company aims to address the low current usage of obesity medications in the US, where less than 2% of individuals with obesity receive treatment [1][3] - Novo Nordisk's chief scientific officer highlighted the importance of patient preference for oral treatments, suggesting that oral semaglutide could increase treatment initiation among those currently untreated [1][3] Industry Insights - The OASIS 4 trial results indicate a significant advancement in obesity treatment options, particularly for oral GLP-1 therapies, which have not been previously approved for weight management [3][6] - Obesity is recognized as a complex disease requiring long-term management, influenced by various factors beyond individual willpower [5][6] - The introduction of oral semaglutide could reshape the landscape of obesity treatment, potentially increasing access and adherence among patients [1][3]

Core Insights - The company reported a 19% increase in net sales for Q1 2025 compared to Q1 2024, reaching DKK 78.1 billion, with operating profit rising by 22% to DKK 38.8 billion [2][3] - The company has revised its full-year sales growth outlook to 13-21% at constant exchange rates (CER), down from previous expectations due to lower-than-planned penetration of branded GLP-1 treatments in the US [3][4] Financial Performance - Net sales for Q1 2025 were DKK 78,087 million, up from DKK 65,349 million in Q1 2024, reflecting a growth of 19% [2] - Operating profit increased to DKK 38,791 million, a 22% rise from DKK 31,846 million in the previous year [2] - Net profit for the quarter was DKK 29,034 million, a 14% increase from DKK 25,407 million in Q1 2024 [2] - Diluted earnings per share rose to DKK 6.53, up 15% from DKK 5.68 [2] Sales Breakdown - Sales in US Operations grew by 20% in Danish kroner and 17% at CER, while International Operations saw an 18% increase in Danish kroner and 19% at CER [4] - Sales in Diabetes and Obesity care increased by 21% to DKK 73.5 billion, driven by a 67% growth in Obesity care to DKK 18.4 billion [4] - GLP-1 diabetes sales grew by 13% in Danish kroner and 11% at CER, while Rare disease sales increased by 5% in Danish kroner and 3% at CER [4] Research and Development - The company completed the REDEFINE 2 trial for CagriSema, showing a weight loss of 15.7% in adults with obesity or overweight and type 2 diabetes [4] - The company has submitted oral semaglutide 25 mg for regulatory review to the US FDA, aiming to be the first oral GLP-1 treatment for obesity [4] - Regulatory submissions for once-weekly semaglutide 2.4 mg have been made in both the EU and US, with priority review granted in the US [4] Outlook - The updated sales growth outlook for 2025 is now expected to be 3 to 5 percentage points lower than previously anticipated when reported in Danish kroner [4] - The company is focused on addressing the challenges posed by compounded GLP-1 treatments in the US and expanding access to its products [3][4]